论文部分内容阅读
目的:了解我院儿科消化性疾病应用微生态制剂的情况。方法:抽查2006年10月～2008年10月儿科住院儿童消化性疾病处方共1 970张,分析微生态制剂的使用及与其他药物的合用情况。结果:涉及微生态制剂处方530张,占被调查处方总数的26.9%,以双歧杆菌三联活菌肠溶胶囊使用频率最高,占微生态制剂处方总数的60.4%。微生态制剂与抗生素合用率83.3%,应用两种微生态制剂的处方为26张,占微生态制剂处方总数的4.9%,无3种及以上微生态制剂合用处方。结论:我院儿科消化性疾病应用微生态制剂不够合理、规范。
Objective: To understand the situation of pediatric digestive diseases using probiotics in our hospital. Methods: A total of 1 970 prescriptions for pediatric digestive diseases were collected from October 2006 to October 2008 in children and analyzed the use of probiotics and their combination with other drugs. Results: 530 prescriptions were involved in probiotics, accounting for 26.9% of the total number of prescriptions tested. The most frequently used enteric-coated Bifidobacterium triple viable bacteria accounted for 60.4% of the total number of prescriptions for probiotics. The combined use rate of probiotics and antibiotics was 83.3%. There were 26 prescriptions for two kinds of probiotics, accounting for 4.9% of the total number of prescriptions for probiotics. There were no prescriptions for three or more kinds of probiotics. Conclusions: The application of probiotics in pediatric digestive diseases in our hospital is not reasonable and standardized.